Former KV chief sentenced to 30 days in jail

Staring down from the bench at the former CEO of KV Pharmaceutical, a federal judge portrayed Marc Hermelin as an example of capitalism gone awry. Hermelin pleaded guilty to two criminal misdemeanor charges of mislabeling drugs. Report

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.